Abstract:Background BEV in combination with fluoropyrimidine-based CT is a standard treatment of mCRC in the first-line (1L) and BEV-naïve second-line (2L) settings. This is the first randomized study evaluating the benefit of continuing BEV in combination with standard CT as 2L treatment of patients with mCRC who progressed after receiving a standard BEV-containing regimen in the 1L setting. Methods Patients with unresectable, histologically confirmed mCRC who progressed within 3 months after discontinuation of 1L BEV + CT were randomized to 2L fluoropyrimidine-based CT ± BEV (2.5 mg/kg/week equivalent). Choice of oxaliplatin- or irinotecan-based 2L CT was dependent on the regimen used in 1L (crossover) and included as a stratification variable. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), response rate and safety. Results Eight hundred and twenty patients were randomized from February 2006 to June 2010. Baseline patient and disease characteristics were well balanced between the arms. The study met its primary end point of OS. Patients who received BEV + CT as 1L for their mCRC and then continued on BEV with a different CT after their cancer progressed lived significantly longer than patients who received only CT in the 2L mCRC. The adverse event profile was consistent with previously reported data for BEV + CT. Compared with the historical data from BEV treatment in 1L or 2L mCRC, BEV-related adverse events were not increased when continuing BEV beyond progression. Conclusions This is the first randomized study to prospectively investigate the impact of continuing BEV treatment in 2L mCRC for patients who progressed after receiving a BEV-containing regimen in 1L. Our findings demonstrate that BEV + CT (crossed over from 1L regimen) continued beyond progression significantly prolongs OS in 2L mCRC. Additional analysis (including biomarker evaluation) is ongoing. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a phase III study (ML 18147) in metastatic colorectal cancer met its primary end point of overall survival. People who received Avastin® (bevacizumab) plus standard chemotherapy as initial treatment (so-called ‘first-line’ treatment) for their metastatic colorectal cancer and then continued on Avastin with a different chemotherapy after their cancer progressed (so-called ‘second-line’ treatment) lived significantly longer than people who received only chemotherapy in the second-line setting. No new safety findings were observed and adverse events were consistent with those seen in previous trials of Avastin. Full data from the ML 18147 study will be submitted for presentation at an upcoming medical meeting.

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer (mcrc): Pooled Analysis from Randomized Controlled Trials (Rcts)

O-0018 Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Overall and Subgroup Analyses of Pooled Data from Randomized Controlled Trials

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis from Seven Randomized Controlled Trials

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

A Prospective Multicenter Observational Study of Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Chinese Patients (obtain Study).

Bevacizumab in Combination with First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer: a Meta-Analysis.

A Prospective, Multicenter, Observational Study of Bevacizumab in Combined with Chemotherapy As First-Line or Second-Line Treatment in Chinese Metastatic Colorectal Cancer

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Efficacy and Safety of Bevacizumab-Based Combination Therapy for Treatment of Patients with Metastatic Colorectal Cancer

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials.

Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

Clinical Efficacy of Bevacizumab Combined with Chemotherapy in the Treatment of Refractory Metastatic Colorectal Cancer

Results of ML18147: A Phase III Study of Bevacizumab in Second-Line MCRC for Patients Pretreated with Bevacizumab in First Line

Efficacy and Safety of Bevacizumab and Chemotherapy in Combination with Atezolizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program.

Efficacy and safety of bevacizumab (BEV)plus chemotherapeutic agents in the treatment of metastatic colorectal cancer (mCRC)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis

Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis.

Primary Tumor Location and Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.

Clinical study of bevacizumab combined with FOLFOX regimen or FOLFIRI regimen for patients with metastatic colorectal cancer